ARKG is trading at $58.57, up 3.17%, as healthcare stocks show strength.
- European healthcare rose 1.6%, led by Genmab after positive late-stage lymphoma results with AbbVie.
- Major U.S. indices are modestly higher, and a generally positive market backdrop may support risk appetite.
- Lilly’s obesity-drug data was recently positive, but Lilly is only 3.40% of ARKG, so it is not enough by itself to explain the ETF’s move.